Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study

Journal of Diabetes Investigation
Yutaka SeinoSoichi Sakai

Abstract

The aim of the present study was to evaluate the safety and efficacy of luseogliflozin added to liraglutide monotherapy in Japanese individuals with type 2 diabetes. This 52-week, multicenter, open-label, single-arm clinical study enrolled Japanese patients who had inadequate glycemic control with diet/exercise and liraglutide monotherapy. Major efficacy end-points included the changes from baseline in glycated hemoglobin, fasting plasma glucose and bodyweight. Body composition was also assessed in individuals who had access to bioelectrical impedance analysis. Safety assessments included adverse events, clinical laboratory tests, vital signs and 12-lead electrocardiograms. Of 76 patients who received luseogliflozin, 62 completed the study. The changes from baseline in glycated hemoglobin, fasting plasma glucose, and bodyweight (mean ± SE) were -0.68 ± 0.10%, -32.1 ± 3.6 mg/dL and -2.71 ± 0.24 kg at week 52, respectively (all, P < 0.001 vs baseline). Luseogliflozin was associated with greater reductions in fat mass than lean mass at all measuring points (n = 22): fat vs lean mass changes (mean ± SE) at week 52 were -2.49 ± 0.45 kg (P < 0.001 vs baseline) and -0.44 ± 0.26 kg (P = 0.107 vs baseline), respectively. Insulin secreti...Continue Reading

References

Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Oct 12, 2010·The New England Journal of Medicine·Sophia ZoungasUNKNOWN ADVANCE Collaborative Group
Oct 28, 2015·Biochemical and Biophysical Research Communications·Seizo OkauchiHideaki Kaneto

❮ Previous
Next ❯

Citations

Jun 22, 2018·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Hisamitsu IshiharaTaishi Sakatani
Sep 22, 2019·Journal of Diabetes Investigation·Yoshihito Fujita, Nobuya Inagaki
Jan 10, 2018·Diabetes, Obesity & Metabolism·Ren MatsubaYasushi Tanaka
May 30, 2020·Journal of Diabetes Investigation·Yusei Hosokawa, Wataru Ogawa
Aug 24, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Taichi Nagahisa, Yoshifumi Saisho
Feb 16, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Haleh ChehrehgoshaMohammad E Khamseh
May 20, 2020·Diabetes Spectrum : a Publication of the American Diabetes Association·John E Anderson

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.